1. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia 
Nobuyoshi Arima, Junya Kanda, Junji Tanaka, Toshio Yabe, Yasuo Morishima, Sung-Won Kim, Yuho Najima, Yukiyasu Ozawa, Tetsuya Eto, Heiwa Kanamori, Takehiko Mori, Naoki Kobayashi, Tadakazu Kondo, Hirohisa Nakamae, Naoyuki Uchida, Masami Inoue, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 4, Pages (April 2018)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Transplantation for hematologic malignancy generates different outcomes. (A and B) Cumulative incidence of leukemia relapse (A) and RFS (B) in 2726 AML recipients who underwent HSCT from an HLA-matched HLA-C1/C1 donor (red dotted line), 350 recipients from an HLA-C1/C2 donor (black solid line), and 39 recipients from an HLA-C2/C2 donor (blue dashed line). (C and D) Forest plot analysis of adjusted ratios (mean and 95% CI) of relapse (C) and RFS (D) between HLA-C1/C1 pairs and HLA-C1/C2 pairs who underwent HLA-matched HSCT for various hematologic malignancies. P values < .10 are described.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Forest plot analysis of transplantation outcomes for each subtype of AML and MDS among HLA-C1/C1 pairs and HLA-C1/C2 pairs. Shown are adjusted ratios (mean and 95% CI) of relapse (A), RFS (B), and OS (C) in recipients of HLA-matched HSCT. P values < .20 are described.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Forest plot analysis of transplantation outcomes in each subgroup of recipients with AML or CML among HLA-C1/C1 pairs and HLA-C1/C2 pairs. Shown are adjusted ratios (mean with 95% CI) of relapse (A) and RFS (B) in recipients who received HLA-matched transplantation. P values < .10 are described.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Transplantation outcomes in HLA-C1/C1 pairs and HLA-C1/C2 pairs in recipients with AML or CML. Cumulative incidence of leukemia relapse in recipients with AML or CML among HLA-C1/C1 pairs (red dashed line) and HLA-C1/C2 pairs (blue solid line) who received peripheral blood stem cell transplantation (A), who experienced prolonged incomplete chimerism (B), and who were depleted of T cells (C). HLA-C1/C2 recipients non-depleted of T cells are shown as a black solid line; HLA-C1/C1 recipients non-depleted of T cells, as a purple dotted line. (D) Adjusted RFS of HLA-C1/C2 recipients (blue solid line) and that of HLA-C1/C1 recipients (red dashed line).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Transplantation outcomes in each generation of recipients with AML or CML among HLA-C1/C1 pairs and HLA-C1/C2 pairs. (A and B) Cumulative incidence of leukemia relapse (A) and RFS (B) in 0- to 15-year-old recipients with HLA-C1/C1 (red dashed line) or HLA-C1/C2 (blue solid line). (C and D) Forest plot analysis among HLA-C1/C1 pairs and HLA-C1/C2 pairs showing ratios (mean with 95% CI) of relapse (C) and RFS (D). P values < .20 are described.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions